The DOI matches its Crossref record; 130 of the 131 references it cites were found in a registry or an index.
Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression
Open accessAbstract
Clinical and preclinical studies suggest that dysfunction of the glutamatergic system is implicated in mood disorders such as major depressive disorder and bipolar depression. In clinical studies of individuals with major depressive disorder and bipolar depression, rapid reductions in depressive symptoms have been observed in response to subanesthetic-dose ketamine, an agent whose mechanism of action involves the modulation of glutamatergic signaling. The findings from these studies have prompted the repurposing and/or development of other glutamatergic modulators for antidepressant efficacy, both as monotherapy or as an adjunct to conventional monoaminergic antidepressants. This review highlights the evidence supporting the antidepressant effects of subanesthetic-dose ketamine as well as other glutamatergic modulators, such as D-cycloserine, riluzole, CP-101,606, CERC-301 (previously known as MK-0657), basimglurant, JNJ-40411813, dextromethorphan, nitrous oxide, GLYX-13, and esketamine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In all reports, initial efficacy was either transient or inconsistent in larger studies [97,103,144,145,146].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [103]
Experimental — accuracy not yet measuredIn the citing paper
“Esketamine has nearly fourfold greater affinity for the NMDAR than (R)-ketamine but interestingly induces fewer and weaker psychotomimetic and dissociative effects [103].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [103]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Larkin, G. L., & Beautrais, A. L. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000629 · Cited by 259
RetractedHamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,526
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Stress signalling pathways that impair prefrontal cortex structure and function
Arnsten, A. F. T. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2648 · Cited by 3,299
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Self-citation
Cited by
Sorted by citations
Items 101–133 of 133
Neurobiology of Suicide in Depressive Disorders
Sönmez, D., Kurhan, F., & Hocaoğlu, Ç. (2024) · Springer eBooks · doi:10.1007/978-3-031-32035-4_152-1 · Cited by 2
Depoortère, R., Papp, M., Gruca, P., Litwa, E., Łasoń, M., Biała, D., & Newman‐Tancredi, A. (2024) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000809 · Cited by 2
Meeting Emerging Challenges and Opportunities in Psychiatry Through Computational Neuroscience
Anticevic, A., Krystal, J. H., & Murray, J. D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809825-7.02004-6 · Cited by 2
Karakatsoulis, G. N., & Fountoulakis, K. Ν. (2022) · Springer eBooks · doi:10.1007/978-3-030-87480-3_8 · Cited by 2
Overview of ketamine for major depression: efficacy and effectiveness
Bahji, A., Vázquez, G. H., Brietzke, E. M., & Zarate, C. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821033-8.00005-8 · Cited by 2
Self-citationGuanine-Based Purines as an Innovative Target to Treat Major Depressive Disorder
Almeida, R. F., Ferreira, T. P., David, C. V. C., Silva, P. C. A. E., dos Santos, S. A., Rodrigues, A. L. S., & Elisabetsky, E. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.652130 · Cited by 2
Ramesh, V., Shamanna, V., Pathak, H., Nayok, S. B., Bose, A., Sreeraj, V. S., & Venkatasubramanian, G. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104302 · Cited by 1
Weigner, D., Meiering, M. S., Weigand, A., Carstens, L., Keicher, C., Hertrampf, R., Beckmann, C. F., Mennes, M., Wunder, A., Gärtner, M., et al. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251346705 · Cited by 1
The VA Ketamine Controversies.
GEPPERT, C. M. A. (2019) · PubMed Central · Cited by 1
Esketamine: the first glutamatergic drug for the management of treatment- resistant depression
Musazzi, L. (2020) · doi:10.36118/pharmadvances.03.2020.02 · Cited by 1
The role of ketamine in the treatment of treatment-resistant bipolar depression
Karakatsoulis, G. N., Tsapakis, E.-M., & Fountoulakis, K. Ν. (2021) · Psychiatriki · doi:10.22365/jpsych.2021.052 · Cited by 1
Nasrallah, H. A. (2022) · Current Psychiatry · doi:10.12788/cp.0283 · Cited by 1
Past, present and future of intravenous anesthetics
Radkowski, P., Czajka, A., Dawidowska-Fidrych, J., & Braczkowska, M. (2024) · Farmacja Polska · doi:10.32383/farmpol/191231 · Cited by 1
Cao, Q., Zhang, N., Leng, C., Wang, S., & Ma, J. (2025) · Reviews in Medical Virology · doi:10.1002/rmv.70036 · Cited by 2
Ketamine and Other Glutamate Receptor Antagonists As Fast-Actin
Chen, M., Su, T., & Tsai, S. (2022) · Neuromethods · doi:10.1007/978-1-0716-2083-0_19 · Cited by 1
Ketamine in Psychiatric Disorders
Danyeli, L. V., Götting, F. N., Şen, Z. D., Li, M., & Walter, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_420 · Cited by 1
Sales, A. J. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2019.tde-27112018-153336 · Cited by 1
Ketamine as a Sedative for Methotrexate-Induced Neurotoxicity with Added NMDA AntagonismPreprint
Ilahi, Z., Janardhan, S., Dave, M., Khariton, M., Feuer, P., Venkataraman, A., & Romanos‐Sirakis, E. (2021) · doi:10.22541/au.161464910.06829960/v1 · Cited by 1
Ketamine in Psychiatric Disorders
Danyeli, L. V., Götting, F. N., Şen, Z. D., Li, M., & Walter, M. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_420-1 · Cited by 1
Grinnell, J. M. (2018) · UND Scholarly Commons (University of North Dakota)
Clinical characteristics and treatment of treatment-resistant bipolar depression
Karakatsoulis, G. N., Tsapakis, E.-M., & Fountoulakis, K. Ν. (2021) · Psychiatriki · doi:10.22365/jpsych.2021.048
Brietzke, E. M., Zarate, C. A., & Vázquez, G. H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821033-8.00008-3
Self-citationKetamine: Recent application in administration of anesthesia, torment and medicare
Komal, K., & Kishor, K. (2023) · AIP conference proceedings · doi:10.1063/5.0113226
Brain Glutamate Dynamics Predict Positive Agency in Healthy WomenPreprint
White, T. L., Gonsalves, M. A., Harris, A. D., Walsh, E. G., & Joyce, H. E. (2023) · Research Square · doi:10.21203/rs.3.rs-3021527/v1
Sex Differences in the Antidepressant Effects of Ketamine
Myers, M. (2023) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2023-15485
Neurobiology of Suicide in Depressive Disorders
Sönmez, D., Kurhan, F., & Hocaoğlu, Ç. (2025) · Springer eBooks · doi:10.1007/978-3-031-73368-0_152
Martin, E. (2017) · theses.fr (ABES) · doi:10.70675/3f77e643zf119z465fzbc28z20877ecebf8e
Chappell, K. (2023) · theses.fr (ABES) · doi:10.70675/5afa484cz21e5z493azae47ze62ca3553104
Kallarackal, J., Dyer, B. J., & Huang, J. (2026) · Springer eBooks · doi:10.1007/978-3-032-25214-2_36
BindingDB (2021) · UC San Diego · doi:10.7270/q2b85cg6
Tang, Q., Feng, J., Hu, C., Feng, J., & Du, D. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119476
Metadata
- Authors
- Lener, M. S., Kadriu, B., & Zarate, C. A.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Lener, Marc S.
- Venue
- Drugs
- Published
- 2017-02-14
- Volume
- 77
- Issue
- 4
- Pages
- 381-401
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- PMC
- PMC5342919
- OpenAlex
- W2588408561
- Cited by
- 131
- References
- 131
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 11 · 2023: 16 · 2022: 18 · 2021: 17 · 2020: 19 · 2019: 14 · 2018: 15 · 2017: 9
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, public-domain)
- Funders
- National Institute of Mental Health (ZIA-MH002857-10)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- ketamine, depression, major depressive disorder, bipolar depression, antidepressant repurposing, subanesthetic ketamine, D-cycloserine, riluzole, CP-101,606, dextromethorphan, nitrous oxide, esketamine, glutamatergic signaling
- MeSH terms
- Depression, Humans, Ketamine, Excitatory Amino Acid Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
